Impact of liver cirrhosis on the outcomes of patients with venous thromboembolism: a case-control study
Introduction
Venous thromboembolism (VTE), which is defined as deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a substantial health-care burden worldwide (1,2). The incidence of VTE is 100–200 per 100,000 person years in the general population (3) and can be as high as 1,000 per 100,000 person years among the elderly patients, cancer patients, and patients with multiple comorbidities (4,5). Population-based epidemiological data has also demonstrated a yearly increased incidence of VTE in Asian patients (6-9). Risk factors of VTE include advanced age, obesity, active cancer, major trauma, fracture, recent surgery, heart failure, respiratory failure, paralytic stroke, inherited thrombophilia, antiphospholipid syndrome, previous VTE, varicose veins, congenital venous malformation, central venous catheter or vena cava filter, long-distance travel, pregnancy/antepartum, oral contraceptives and hormone replacement therapy (3,10-17). VTE is associated with reduced survival and substantial health-care costs (18,19). Prognostic factors of VTE include advanced age, male, lower body mass index, confinement to a hospital or nursing home at the onset of VTE, congestive heart failure, chronic lung disease, serious neurologic disease, tumor stage, tumor location, and absence of timely treatment (20-24). In Europe, more than 500,000 deaths per annum are attributable to VTE and its associated complications (3).
Recently, the association of VTE with liver cirrhosis has been frequently explored. However, the impact of liver cirrhosis on the outcomes of VTE remains unclear. Herein, we conducted a case-control study to explore the difference in the clinical characteristics and outcomes between VTE patients with and without cirrhosis.
Methods
Patients
The protocol of our study was approved by the Ethics Committee of General Hospital of Shenyang Military Area (approval number: k201602). Informed written consents were waived. The diagnoses of VTE were identified by searching the International Classification Codes (ICD)-9 and discharge diagnoses in the Department of Information between January 2011 and December 2015. ICD for the diagnosis of DVT include 453, 453.4, 453.4X, 453.5X, 453.7X, 453.8X, and 451.1–451.8. ICD for the diagnosis of PE include 415.1 and 415.1X. ICD for the diagnosis of liver cirrhosis include 571, 571.2, 571.5, and 571.6.
Diagnosis of VTE was established in accordance with the medical history of thrombosis, clinical presentations, laboratory tests, and imaging examinations. DVT was confirmed by the venography, compression Doppler ultrasound, CT scan, MRI scan, or autopsy. PE was confirmed by the pulmonary angiography, spiral CT scan, MRI scan, or pathology and ventilation-perfusion scan. Diagnosis of liver cirrhosis was established in accordance with the medical history of liver disease, clinical presentations, laboratory tests, and abdominal imaging.
Cases
Case and control group were defined as VTE with and without liver cirrhosis, respectively. Patients with malignancy and repeated admission were excluded. For each identified patient with VTE and liver cirrhosis in the case group, ten patients with VTE and without liver cirrhosis in the control group were matched by the age, sex, and Charlson Comorbidity Index score (CCIs). Some patients had been included in our previous studies (9,25-28).
Data collection
An investigator (Xintong Zhang) searched the medical records regarding medical history and new onset of VTE and another investigator (Xingshun Qi) checked the data accuracy. We collected the ages, genders, total CCIs, histories of smoking, alcohol and hypertension, etiologies of liver disease, locations and final diagnostic methods of VTE, antithrombotic drugs, dosages, and lengths, lengths of stay, laboratory data (white blood cell, red blood cell, hemoglobin, platelet, C-reactive protein, total bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, albumin, glutamyltranspeptidase, blood urea nitrogen, creatinine, potassium, sodium, total cholesterin, triglyceride, international normalized ratio (INR), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, and D-dimer). Locations of major bleeding and causes of in-hospital death were reviewed.
Definitions
CCIs, which were evaluated and validated for the prognostic assessment in different clinical contexts (29), were divided into four classes: group 1 (CCIs: 4), group 2 (CCIs: 5), group 3 (CCIs: 6), and group 4 (CCIs: ≥6) (Table S1). Definition and classification of arterial hypertension were determined according to the guideline (30). Child-Pugh score was calculated according to the previous criteria (31). Major bleeding was defined in accordance with the International Society on Thrombosis and Haemostasis (ISTH) criteria (symptomatic bleeding in a critical organ; bleeding causing a fall in the hemoglobin of at least 20 g/L or leading to transfusion of at least two units of whole blood or red blood cells; or fatal bleeding) (32).
Statistical analysis
Statistical analysis was performed using SPSS Statistics version 19.0.0. Continuous variables were compared between the case group and the control group using the independent sample t-test or the Wilcoxon signed-rank test. Categorical variables were compared using Chi-square test or Fisher exact test. Bar chart was drawn to compare the incidence of major bleeding and in-hospital mortality between VTE patients with and without cirrhosis. A two sided P<0.05 was considered to be statistically significant.
Results
Patients
Sixteen patients with both VTE and cirrhosis were included in the case group (Table 1). Among them, eight patients were diagnosed with DVT, six patients with PE, and two patients with both DVT and PE; eight patients had a previous history of lower extremity DVT, five patients had a previous history of PE, one patient had a previous history of both DVT and PE, one patient had a previous history of DVT and developed PE during hospitalization, and one patient developed PE during hospitalization.
Table 1
| Age | Sex | CCIs | CCI related diseases | Locations | Child-Pugh score | Causes of liver disease |
|---|---|---|---|---|---|---|
| 40 | F | 4 | Moderate or severe liver disease + peripheral disease | DVT | 7 | Unknown |
| 42 | F | 4 | Moderate or severe liver disease + peripheral disease | PE + DVT | 11 | HBV |
| 46 | M | 4 | Moderate or severe liver disease + peripheral disease | DVT | 8 | Alcohol |
| 48 | M | 4 | Moderate or severe liver disease + peripheral disease | PE | 8 | Alcohol + HCV |
| 52 | M | 4 | Moderate or severe liver disease + peripheral disease | DVT | 9 | Alcohol + HBV |
| 54 | F | 5 | Moderate or severe liver disease + peripheral disease + chronic pulmonary disease | DVT | 8 | Alcohol + PBC |
| 56 | M | 5 | Moderate or severe liver disease + peripheral disease + diabetes without end-organ damage | DVT | 11 | Alcohol |
| 56 | M | 5 | Moderate or severe liver disease + peripheral disease + diabetes without end-organ damage | DVT | 10 | Alcohol + HBV |
| 63 | M | 5 | Moderate or severe liver disease + peripheral disease + peptic ulcer disease | PE | 8 | Alcohol |
| 75 | F | 5 | Moderate or severe liver disease + peripheral disease + cerebrovascular disease | PE | 10 | Alcohol |
| 47 | M | 6 | Moderate or severe liver disease + peripheral disease + diabetes without end-organ damage + chronic pulmonary disease | PE | 7 | Alcohol + HBV |
| 54 | M | 6 | Moderate or severe liver disease + peripheral disease + history of myocardial infarction + cerebrovascular disease | DVT | 8 | Alcohol |
| 71 | M | 6 | Moderate or severe liver disease + peripheral disease + diabetes without end-organ damage + history of myocardial infarction | DVT | 10 | HBV |
| 59 | M | 7 | Moderate or severe liver disease + peripheral disease + history of myocardial infarction + moderate or severe renal disease | PE + DVT | 9 | HBV |
| 69 | M | 7 | Moderate or severe liver disease + peripheral disease + chronic pulmonary disease + moderate or severe renal disease | PE | 7 | Unknown |
| 80 | F | 8 | Moderate or severe liver disease + peripheral disease + chronic pulmonary disease + history of myocardial infarction + moderate or severe renal disease | PE | 9 | HBV |
CCI, Charlson Comorbidity Index; DVT, deep vein thrombosis; PE, pulmonary embolism; HBV, hepatitis B virus; HCV, hepatitis C virus; PBC, primary biliary cirrhosis.
One hundred and sixty patients were included in the control group. Among them, 25 patients were diagnosed with DVT, 91 patients with PE, and 44 patients with both DVT and PE; 23 patients had a previous history of lower extremity DVT, 58 patients had a previous history of PE, 32 patients had a previous history of both DVT and PE, 11 patients had a previous history of DVT and developed PE during hospitalization, 2 patients developed DVT during hospitalization, 33 patients developed PE during hospitalization, and 1 patient developed both DVT and PE during hospitalization. The age, sex, and total CCIs were comparable between the two groups.
Clinical characteristics between case and control groups
Clinical characteristics were compared between case and control groups (Table 2). The case group had a significantly higher proportion of history of alcohol than the control group [50% (8/16) vs.15% (24/160), P=0.002]. Red blood cell and platelet count were significantly lower in the case group than the control group (3.66±0.99 vs. 4.08±0.76, P=0.044; 113.56±78.84 vs. 197.23±105.34, P=0.002, respectively). Albumin was significantly lower in the case group than the control group (31.2±7.50 vs. 35.55±6.40, P=0.012). Total cholesterin was significantly lower in the case group than the control group (3.11±1.31 vs. 4.56±1.81, P=0.006). PT, APTT and INR were significantly higher in the case group than the control group (22.43±8.36 vs. 14.63±3.95, P=0.015; 47.20±14.24 vs. 38.35±8.97, P<0.001; 1.80±0.88 vs. 1.19±0.43, P=0.014, respectively). Fibrinogen was significantly lower in the case group than the control group (2.88±1.76 vs. 3.90±1.69, P=0.022). Child-Pugh score was significantly higher in the case group than the control group (8.75±1.34 vs. 5.90±1.09, P<0.001).
Table 2
| Variables | Case group (n=16) | Control group (n=160) | P value | |||
|---|---|---|---|---|---|---|
| No. pts available | Results | No. pts available | Results | |||
| Age (year) | 16 | 57.00±11.81; 55 [41–80] | 160 | 59.70±11.80; 60 [37–84] | 0.384 | |
| Sex (M/F) | 16 | 11/5 | 160 | 110/50 | 1.000 | |
| CCIs | 16 | 5.31±1.25; 5 [4–8] | 160 | 5.33±1.25; 5 [4–8] | 0.970 | |
| History of alcohol (Y/N) | 16 | 8/8 | 160 | 24/136 | 0.002 | |
| History of smoking (Y/N) | 16 | 9/7 | 160 | 49/111 | 0.051 | |
| Hypertension (Y/N) | 16 | 5/11 | 160 | 65/95 | 0.596 | |
| Red blood cell (1012/L) | 16 | 3.66±0.99; 3.45 (1.34–5.19) | 156 | 4.08±0.76; 4.09 (2.05–5.94) | 0.044 | |
| Hemoglobin (g/L) | 16 | 115.5±31.53; 121 [39–155] | 156 | 125.94±24.68; 127 [60–199] | 0.119 | |
| White blood cell (109/L) | 16 | 8.71±6.61; 6.2 (2.1–27.6) | 156 | 8.10±3.38; 7.25 (2.7–20.8) | 0.720 | |
| Platelet (109/L) | 16 | 113.56±78.84; 84 [28–348] | 156 | 197.23±105.34; 185.5 [39–1,153] | 0.002 | |
| C-reactive protein (mg/L) | 6 | 116.58±105.83; 90.85 (3.2–313.0) | 54 | 41.28±46.26; 19.2 (1.9–216) | 0.143 | |
| Total bilirubin | 16 | 42.26±66.90; 24.7 (3.5–285.6) | 154 | 15.72±12.08; 12.3 (1.9–65.0) | 0.134 | |
| Direct bilirubin | 16 | 22.78±43.00; 13.1 (1.8–181.8) | 154 | 5.97±5.63; 4.35 (0.1–35.3) | 0.139 | |
| Alanine aminotransferase (U/L) | 16 | 386.89±1094.60; 32 [7–4,307] | 156 | 52.91±242.22; 19 [4–2,995] | 0.242 | |
| Aspartate aminotransferase (U/L) | 16 | 532.99±1549.40; 38 [17–6,209] | 156 | 54.35±214.03; 22 [9–2,603] | 0.236 | |
| Albumin (g/L) | 16 | 31.2±7.50; 34.05 (17.4–41.2) | 139 | 35.55±6.40; 36.1 (12.6–48.2) | 0.012 | |
| Glutamyl transpeptidase (U/L) | 16 | 101.03±109.98; 67 [8–415] | 155 | 76.09±98.02; 46 [8–860] | 0.339 | |
| Blood urea nitrogen (mmol/L) | 16 | 8.25±5.24; 6.70 (2.96–20.91) | 148 | 8.60±6.58; 6.94 (2.55–45.70) | 0.841 | |
| Creatinine (μmol/L) | 16 | 109.83±120.00; 71 (38.1–524) | 148 | 106.57±148.20; 73.5 (30.8–1,346.7) | 0.935 | |
| Potassium (mmol/L) | 16 | 4.16±0.75; 3.98 (3.2–5.7) | 155 | 4.03±0.57; 4.03 (2.2–6.2) | 0.407 | |
| Sodium (mmol/L) | 16 | 138.95±4.07; 138.5 (130.8–146.0) | 155 | 138.96±4.54; 139 (123.9–155.5) | 0.994 | |
| Total cholesterin (mmol/L) | 6 | 3.11±1.31; 2.81 (1.86–4.77) | 84 | 4.56±1.81; 4.09 (2.33–12.99) | 0.006 | |
| Triglyceride (mmol/L) | 6 | 0.86±0.39; 0.85 (0.22–1.39) | 84 | 1.84±2.11; 1.37 (0.45–16.23) | 0.260 | |
| Prothrombin time at admission (second) | 16 | 22.43±8.36; 16.5 (12.9–38.8) | 159 | 14.63±3.95; 13.6 (10.2–37.9) | 0.015 | |
| Activated partial thromboplastin time at admission (second) | 16 | 47.20±14.24; 45.5 (26.2–87.3) | 159 | 38.35±8.97; 37.7 (0.9–76.1) | 0.001 | |
| International normalized ratio at admission | 16 | 1.80±0.88; 1.39 (1.00–3.37) | 159 | 1.19±0.43; 1.07 (0.78–4.07) | 0.014 | |
| Fibrinogen at admission | 16 | 2.88±1.76; 2.64 (1.25–8.43) | 157 | 3.90±1.69; 3.6 (0.53–13.85) | 0.022 | |
| D-dimer at admission (μg/mL) | 13 | 3.59±4.36; 1.7 (0.1–15.5) | 156 | 2.42±9.21; 0.4 (0.1–80) | 0.065 | |
| Child-Pugh scores | 16 | 8.75±1.34; 8.5 [7–11] | 160 | 5.90±1.09; 6 [5–10] | 0.000 | |
Antithrombotic therapies between case and control group
In the case group, 7 patients received anticoagulant therapies and 1 patient received both anticoagulant and thrombolytic therapies (Table S2). Anticoagulants included low molecular weight heparin alone (n=4), warfarin alone (n=2), and both low molecular weight heparin and warfarin (n=2). Thrombolytics included alteplase (n=1) for acute stage of PE.
In the control group, 134 patients received anticoagulant therapies and 11 patients received both anticoagulant and thrombolytic therapies (Table S3). Anticoagulants included low molecular weight heparin alone (n=59), unfractionated heparin alone (n=5), warfarin alone (n=15), both low molecular weight heparin and warfarin (n=64), and both unfractionated heparin and warfarin (n=2). Thrombolytics included alteplase (n=8) and urokinase (n=3) for acute stage of PE.
Rate of antithrombotic therapies was significantly lower in the case group than the control group [50% (8/16) vs. 90.6% (145/160), P<0.001].
Rate of anticoagulant therapies was significantly lower in the case group than the control group [50% (8/16) vs. 90.6% (145/160), P<0.001]. The ratio of length of anticoagulant therapy to that of hospital stay was significantly lower in the case group than the control group (41% vs. 87%, P<0.001).
Rate of thrombolytic therapies was not significantly different between case and control groups [6.25% (1/16) vs. 6.88% (11/160), P=1.000].
Major bleeding between case and control group
The incidence of major bleeding was significantly higher in the case group than the control group [43.8% (7/16) vs. 13.8% (22/160), P=0.006]. Location of major bleeding was shown in Table 3. After the exclusion of variceal bleeding, the incidence of major bleeding was not significantly different between case and control groups [6.2% (1/16) vs. 13.8% (22/160), P=0.698].
Table 3
| Locations | Case | Control |
|---|---|---|
| Gastrointestinal bleeding | 7 | 9 |
| Variceal bleeding confirmed by endoscopy | 6 | 0 |
| Ulcer confirmed by endoscopy | 0 | 2 |
| Intestinal bleedings confirmed by endoscopy | 0 | 1 |
| Hemobilia | 0 | 1 |
| Unknown source or no endoscopic examination | 1 | 5 |
| Respiratory bleeding | 0 | 3 |
| Hemoptysis | 0 | 2 |
| Intracranial hemorrhage | 0 | 1 |
| Unknown | 0 | 7 |
| Total | 7 | 22 |
In the case group, the incidence of major bleeding was not significantly different between patients who received and did not receive anticoagulant therapies [25% (2/8) vs. 62.5% (5/8), P=0.315]. The interval between the initiation of anticoagulation and occurrence of major bleeding is 5 or 6 days in the two patients who received anticoagulant therapies (Table S2). The incidence of major bleeding was not significantly different between patients who received and did not receive thrombolytic therapies [0% (0/1) vs. 46.7% (7/15), P=1.000].
In the control group, the incidence of major bleeding was not significantly different between patients who received and did not receive anticoagulant therapies [13.1% (19/145) vs. 20% (3/15), P=0.437]. The average interval between the initiation of anticoagulation and occurrence of major bleeding is 5.21 (1-12) days in the patients who received anticoagulant therapies (Table S3). The incidence of major bleeding was not significantly different between patients who received and did not receive thrombolytic therapies [0% (0/11) vs. 14.8% (22/149), P=0.364].
In-hospital mortality between case and control group
The in-hospital mortality was significantly higher in the case group than the control group [37.5% (6/16) vs. 7.5% (12/160), P=0.002]. Causes of death were shown in Table 4.
Table 4
| Causes | Case | Control |
|---|---|---|
| Massive gastrointestinal bleeding | 1 | 0 |
| Liver failure | 1 | 0 |
| Pulmonary embolism + multiple organ failure | 1 | 0 |
| Pulmonary embolism | 2 | 2 |
| Acute myocardial infarction | 1 | 1 |
| Respiratory failure | 0 | 5 |
| Respiratory failure + massive gastrointestinal bleeding | 0 | 1 |
| Multiple organ failure | 0 | 2 |
| Cerebrovascular disease | 0 | 1 |
| Total | 6 | 12 |
In the case group, the in-hospital mortality was not significantly different between patients who received and did not receive anticoagulant therapies [25% (2/8) vs. 50% (4/8), P=0.608]. The in-hospital mortality was not significantly different between patients who received and did not receive thrombolytic therapies [100% (1/1) vs. 33.3% (5/15), P=0.375].
In the control group, the in-hospital mortality was not significantly different between patients who received and did not receive anticoagulant therapies [7.6% (11/145) vs. 6.7% (1/15), P=1.000]. The in-hospital mortality was not significantly different between patients who received or did not receive thrombolytic therapies [0% (0/11) vs. 8.1% (12/149), P=1.000].
Discussion
The mortality of VTE in our study appears to be higher than the results of the Framingham Heart Study that the mortality of VTE was 145/1,000 person years (33). This phenomenon might be explained by a higher proportion of patients with CCIs of greater than 4 and a higher proportion of patients with PE in our study.
Our study demonstrated that liver cirrhosis had an unfavorable impact on the in-hospital outcomes of VTE patients. This finding seems to be consistent with that of Spencer et al. (34) that sicker patients are more prone to thromboembolic events and have worse prognosis. Liver cirrhosis is an end-stage of liver diseases and is often complicated by lethal portal hypertension related complications, such as variceal bleeding, ascites, encephalopathy, and infection (35). Obviously, our cirrhotic patients had higher total bilirubin, alanine aminotransferase, aspartate aminotransferase, glutamyltranspeptidase, and Child-Pugh scores and lower albumin due to liver dysfunction.
Current practice guideline provides a class 1A recommendation for the administration of thromboprophylaxis in patients with VTE. However, such recommendations may be inappropriate to the patients with liver cirrhosis (36). Use of anticoagulation for the prophylaxis and treatment of VTE in cirrhosis remains controversial due to the potential bleeding risk. Recently, several studies have demonstrated the safety of anticoagulants in patients with cirrhosis (37-40). Our previous systematic review showed that the pooled incidence of bleeding in cirrhotic patients receiving anticoagulation was 3.3% (40). By comparison, the present study demonstrated a higher rate of major bleeding in cirrhotic patients receiving anticoagulation, which was more likely attributed to a higher CCI of ≥4. Patients with liver cirrhosis had a higher rate of major bleeding than those without. Indeed, after excluding variceal bleeding, the rate of major bleeding was lower in patients with liver cirrhosis than those without. This phenomenon suggested that the risk of bleeding in such patients should be primarily due to portal hypertension, but not systemic haemostatic impairment.
We found that the risk of major bleeding was not significantly associated with anticoagulation in patients with liver cirrhosis and VTE. In addition, there is no statistically significant association between anticoagulation and an increased risk of in-hospital death in such patients. Notably, the in-hospital mortality might be lower in cirrhotic patients with VTE who received anticoagulation than those who did not receive anticoagulation. This might reflect the benefits of anticoagulation in resolving VTE and improving the survival. Thus, anticoagulant therapy, rather than a “wait-and-see” strategy, might be considered for the management of VTE in liver cirrhosis.
Our study had several limitations. First, the patient selection bias should not be neglected due to the retrospective study in a single-center even though we have very few exclusion criteria. Second, the absence of analyses regarding therapeutic administration route (41) and dosages and quality of anticoagulation (42) may restrict our interpretation about the impact of anticoagulation. Third, there was a relatively small sample size of patients with cirrhosis and VTE. The statistical power is hardly achieved in some analyses.
In conclusion, liver cirrhosis may increase the incidence of major bleeding and in-hospital mortality in patients with VTE. Anticoagulant therapy may not be associated with the risk of major bleeding and in-hospital mortality in cirrhotic patients with VTE. Well-designed prospective randomized controlled trials are warranted to establish the risks and benefits of anticoagulation for VTE in cirrhosis.
Table S1
| Comorbidity | Scores |
|---|---|
| History of myocardial infarction | +1 |
| Congestive heart failure | +1 |
| Cerebrovascular disease | +1 |
| Chronic pulmonary disease | +1 |
| Connective tissue disease | +1 |
| Peptic ulcer disease | +1 |
| Mild liver disease (no portal hypertension, includes chronic hepatitis) | +1 |
| Diabetes without end-organ damage | +1 |
| Peripheral disease | +1 |
| Hemiplegia | +2 |
| Moderate or severe renal disease | +2 |
| Diabetes with end-organ damage | +2 |
| Moderate or severe liver disease | +3 |
| AIDS | +6 |
AIDS, acquired immune deficiency syndrome.
Table S2
| No. | Acute stage of VTE | Anticoagulants | Dosages of anticoagulants before major bleeding or during hospitalization | Frequency of anticoagulants (per day) | Thrombolytics | Dosages of thrombolytics before major bleeding or during hospitalization | Frequency of thrombolytics (per day) | Major bleeding | Interval between major bleeding and use of anticoagulants (days) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | No | Warfarin | 3 mg | 1 | – | – | – | No | – |
| 2 | No | Warfarin | 3 mg | 1 | – | – | – | No | – |
| 3 | No | Low molecular weight heparin calcium | 5,000 iu | 2 | – | – | – | Yes | 6 |
| 4 | Yes | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 2.5 mg | 2; 1 | Alteplase | 50 mg | 1 | No | – |
| 5 | No | Low molecular weight heparin calcium | 4,000 iu | 1 | – | – | – | Yes | 5 |
| 6 | No | Low molecular weight heparin calcium | 6,400 iu | 2 | – | – | – | No | – |
| 7 | No | Low molecular weight heparin calcium | 4,250 iu | 2 | – | – | – | No | – |
| 8 | No | Low molecular weight heparin calcium; Warfarin | 6,100 u; 2.5 mg | 2; 1 | – | – | – | No | – |
Table S3
| No. | Acute stage of VTE | Anticoagulants | Dosages of anticoagulants before major bleeding or during hospitalization | Frequency of anticoagulants (per day) | Thrombolytics | Dosages of thrombolytics before major bleeding or during hospitalization | Frequency of thrombolytics (per day) | Major bleeding | Interval between major bleeding and use of anticoagulants (days) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | No | Enoxaparin | 20 mg | 1 | No | ||||
| 2 | Yes | Low molecular weight heparin calcium | 5,000 iu | 2 | Yes | 1 | |||
| 3 | No | Low molecular weight heparin calcium | 4,250 iu | 1 | No | ||||
| 4 | No | Low molecular weight heparin calcium | 5,000 iu | 2 | No | ||||
| 5 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 3 mg | 1; 1 | No | ||||
| 6 | No | Enoxaparin | 40 mg | 1 | Yes | 3 | |||
| 7 | Yes | Enoxaparin | 70 mg | 2 | Yes | 4 | |||
| 8 | No | Enoxaparin; Warfarin | 40 mg; 2.25 mg | 2; 1 | Yes | 5 | |||
| 9 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3 mg | 2; 1 | Yes | 6 | |||
| 10 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 3 mg | 1; 1 | No | ||||
| 11 | No | Enoxaparin | 80 mg | 2 | No | ||||
| 12 | No | Low molecular weight heparin calcium | 5,000 iu | 2 | No | ||||
| 13 | No | Fondaparinux sodium | 2.5 mg | 1 | No | ||||
| 14 | No | Low molecular weight heparin calcium | 4,250 iu | 2 | No | ||||
| 15 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3 mg | 2; 1 | No | ||||
| 16 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 3 mg | 1; 1 | No | ||||
| 17 | No | Low molecular weight heparin calciumWarfarin | 5,000 iu; 3 mg | 2; 1 | No | ||||
| 18 | No | Low molecular weight heparin calcium | 5,000 iu | 1 | Yes | 6 | |||
| 19 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 4.5 mg | 1; 1 | No | ||||
| 20 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 3 mg | 2; 1 | No | ||||
| 21 | No | Warfarin | 3 mg | 1 | No | ||||
| 22 | Yes | Low molecular weight heparin sodium | 6,375 iu | 2 | Urokinase | 50 wu | 1 | No | |
| 23 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 32.5 mg | 2; 1 | No | ||||
| 24 | No | Warfarin | 3 mg | 1 | No | ||||
| 25 | No | Enoxaparin; Warfarin | 60 mg; 2.75 mg | 2; 1 | No | ||||
| 26 | No | Heparin calcium; Warfarin | 3,750 u; 3.75 mg | 1; 2 | No | ||||
| 27 | Yes | Enoxaparin | 40 mg | 1 | Yes | 5 | |||
| 28 | No | Low molecular weight heparin calcium | 5,000 iu | 1 | No | ||||
| 29 | Yes | Low molecular weight heparin calcium | 5,000 iu | 1 | No | ||||
| 30 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3 mg | 2; 1 | No | ||||
| 31 | No | Enoxaparin | 40 mg | 2 | No | ||||
| 32 | No | Warfarin | 2.25 mg | 1 | No | ||||
| 33 | Yes | Low molecular weight heparin calcium | 4,250 iu | 2 | Yes | 8 | |||
| 34 | Yes | Low molecular weight heparin calcium | 4,250 iu | 1 | No | ||||
| 35 | Yes | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 6 mg | 2; 1 | No | ||||
| 36 | Yes | Heparin calcium | 7,500 u | 1 | No | ||||
| 37 | Yes | Low molecular weight heparin calcium | 4,250 iu | 2 | Alteplase | 50 mg | Once | No | |
| 38 | No | Low molecular weight heparin calcium | 5,000 iu | 2 | No | ||||
| 39 | Yes | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 3 mg | 2; 1 | No | ||||
| 40 | No | Low molecular weight heparin calcium | 5,000 iu | 2 | No | ||||
| 41 | No | Warfarin | 3 mg | 1 | No | ||||
| 42 | Yes | Low molecular weight heparin calcium | 5,000 iu | 2 | No | ||||
| 43 | Yes | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 4.5 mg | 2; 1 | No | ||||
| 44 | No | Low molecular weight heparin calcium | 5,000 iu | 2 | No | ||||
| 45 | Yes | Low molecular weight heparin calcium | 4,250 iu | 2 | No | ||||
| 46 | Yes | Enoxaparin | 40 mg | 2 | No | ||||
| 47 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 2.5 mg | 2; 1 | Yes | 4 | |||
| 48 | No | Low molecular weight heparin calcium | 4,250 iu | 1 | No | ||||
| 49 | No | Low molecular weight heparin sodium | 6,375 iu | 2 | No | ||||
| 50 | Yes | Low molecular weight heparin calcium | 5,000 iu | 2 | No | ||||
| 51 | Yes | Enoxaparin; Warfarin | 85 mg; 4.5 mg | 2; 1 | No | ||||
| 52 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3.25 mg | 2; 1 | No | ||||
| 53 | No | Warfarin | 3 mg | 1 | No | ||||
| 54 | No | Warfarin | 3 mg | 1 | No | ||||
| 55 | Yes | Heparin calcium | 5,000 u | 2 | No | ||||
| 56 | Yes | Warfarin | 4.5 mg | 1 | No | ||||
| 57 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 3.5 mg | 1; 1 | No | ||||
| 58 | No | Enoxaparin | 40 mg | 2 | No | ||||
| 59 | No | Warfarin | 3 mg | 1 | No | ||||
| 60 | No | Warfarin | 3 mg | 1 | No | ||||
| 61 | No | Warfarin | 3 mg | 1 | No | ||||
| 62 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 4 mg | 2; 1 | No | ||||
| 63 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 2.75 mg | 2; 1 | No | ||||
| 64 | No | Enoxaparin | 60 mg | 2 | No | ||||
| 65 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3 mg | 2; 1 | No | ||||
| 66 | No | Low molecular weight heparin calcium | 4,000 iu | 1 | Yes | 6 | |||
| 67 | No | Low molecular weight heparin calcium | 5,000 iu | 2 | No | ||||
| 68 | Yes | Enoxaparin | 60 mg | 2 | No | ||||
| 69 | Yes | Low molecular weight heparin calcium | 4,250 iu | 2 | No | ||||
| 70 | Yes | Enoxaparin | 40 mg | 2 | No | ||||
| 71 | Yes | Low molecular weight heparin sodium | 6,375 iu | 2 | No | ||||
| 72 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 1.5 mg | 2; 1 | No | ||||
| 73 | Yes | Enoxaparin | 40 mg | 2 | No | ||||
| 74 | No | Low molecular weight heparin calcium | 4,250 iu | 2 | No | ||||
| 75 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 3.5 mg | 1; 1 | Yes | 2 | |||
| 76 | Yes | Low molecular weight heparin sodium | 6,375 iu | 2 | No | ||||
| 77 | No | Low molecular weight heparin sodium | 6,375 iu | 1 | No | ||||
| 78 | Yes | Low molecular weight heparin calcium; Warfarin | 4,000 iu; 2.5 mg | 1; 1 | Urokinase | 50 wu | 1 | No | |
| 79 | No | Low molecular weight heparin calcium | 7,000 iu | 2 | No | ||||
| 80 | No | Low molecular weight heparin calcium | 4,250 iu | 2 | Yes | 3 | |||
| 81 | No | Low molecular weight heparin calcium | 5,000 iu | 2 | No | ||||
| 82 | Yes | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 4 mg | 2; 1 | Alteplase | 50 mg | Once | No | |
| 83 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 4 mg | 2; 1 | No | ||||
| 84 | No | Warfarin | 3 mg | 1 | No | ||||
| 85 | No | Low molecular weight heparin calcium | 4,250 iu | 2 | No | ||||
| 86 | No | Warfarin | 3.25 mg | 1 | No | ||||
| 87 | Yes | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3 mg | 2; 1 | Urokinase | 50 wu | 1 | No | |
| 88 | Yes | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 4 mg | 2; 1 | Alteplase | 50 mg | Once | No | |
| 89 | Yes | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 4 mg | 2; 1 | Alteplase | 50 mg | Once | No | |
| 90 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 3.5 mg | 2; 1 | Yes | 8 | |||
| 91 | Yes | Fondaparinux sodium; Warfarin | 2.5 mg; 3.5 mg | 1; 1 | No | ||||
| 92 | No | Warfarin | 3 mg | 1 | No | ||||
| 93 | Yes | Heparin calcium | 7,500 u | 2 | No | ||||
| 94 | No | Enoxaparin; Warfarin | 40 mg; 3 mg | 2; 1 | No | ||||
| 95 | Yes | Low molecular weight heparin calcium | 5,000 iu | 2 | No | ||||
| 96 | No | Low molecular weight heparin calcium | 4,250 iu | 2 | No | ||||
| 97 | No | Low molecular weight heparin calcium | 5,000 iu | 2 | Yes | 1 | |||
| 98 | Yes | Low molecular weight heparin sodium | 6,375 iu | 2 | No | ||||
| 99 | No | Enoxaparin | 40 mg | 2 | No | ||||
| 100 | No | Enoxaparin; Warfarin | 60 mg; 3 mg | 2; 1 | No | ||||
| 101 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 2.5 mg | 2; 1 | Yes | 8 | |||
| 102 | No | Low molecular weight heparin calcium; Warfarin | 6,000 iu; 3 mg | 2; 1 | No | ||||
| 103 | No | Fondaparinux sodium; Warfarin | 2.5 mg; 1.5 mg | 1; 1 | No | ||||
| 104 | No | Enoxaparin; Warfarin | 40 mg; 3 mg | 2; 1 | No | ||||
| 105 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 5 mg | 2; 1 | No | ||||
| 106 | No | Low molecular weight heparin calcium | 4,250 iu | 2 | No | ||||
| 107 | Yes | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 2 mg | 2; 1 | Alteplase | 50 mg | Once | No | |
| 108 | No | Enoxaparin; Warfarin | 60 mg; 3 mg | 2; 1 | No | ||||
| 109 | Yes | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 1 mg | 2; 1 | No | ||||
| 110 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 2.5 mg | 2; 1 | No | ||||
| 111 | No | Enoxaparin; Warfarin | 20 mg; 2.75 mg | 2; 1 | No | ||||
| 112 | Yes | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3 mg | 2; 1 | Alteplase | 50 mg | Once | No | |
| 113 | No | Enoxaparin; Warfarin | 40 mg; 3 mg | 2; 1 | No | ||||
| 114 | Yes | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3 mg | 2; 1 | Alteplase | 50 mg | Once | No | |
| 115 | No | Low molecular weight heparin sodium | 6,375 iu | 2 | No | ||||
| 116 | No | Warfarin | 3 mg | 1 | No | ||||
| 117 | No | Low molecular weight heparin calcium | 5,000 iu | 2 | No | ||||
| 118 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 2.75 mg | 2; 1 | No | ||||
| 119 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 3 mg | 2; 1 | No | ||||
| 120 | No | Heparin calcium; Warfarin | 3,750 u; 4.5 mg | 1; 1 | No | ||||
| 121 | No | Enoxaparin | 40 mg | 2 | No | ||||
| 122 | Yes | Heparin calcium | 7,500 u | 2 | Yes | 7 | |||
| 123 | Yes | Low molecular weight heparin calcium | 4,000 iu | 2 | Yes | 3 | |||
| 124 | Yes | Low molecular weight heparin calcium; Warfarin | 4,000 iu; 3 mg | 2; 1 | Yes | 12 | |||
| 125 | No | Fondaparinux sodium; Warfarin | 2.5 mg; 3 mg | 1; 1 | No | ||||
| 126 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 2.75 mg | 2; 1 | No | ||||
| 127 | No | Fondaparinux sodium; Warfarin | 2.5 mg; 22.5 mg | 1; 1 | No | ||||
| 128 | No | Enoxaparin | 60 mg | 2 | No | ||||
| 129 | No | Warfarin | 3 mg | 1 | No | ||||
| 130 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 3 mg | 2; 1 | No | ||||
| 131 | No | Fondaparinux sodium | 2.5 mg | 1 | No | ||||
| 132 | No | Low molecular weight heparin calcium; Warfarin | 6,000 iu; 2.5 mg | 2; 1 | No | ||||
| 133 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3 mg | 2; 1 | No | ||||
| 134 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3.25 mg | 2; 1 | No | ||||
| 135 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 2.75 mg | 2; 1 | No | ||||
| 136 | No | Enoxaparin; Warfarin | 40 mg; 3 mg | 2; 1 | No | ||||
| 137 | No | Low molecular weight heparin calcium; Warfarin | 5,000 iu; 3 mg | 2; 1 | No | ||||
| 138 | No | Enoxaparin; Warfarin | 40 mg; 2.75 mg | 2; 1 | No | ||||
| 139 | Yes | Enoxaparin; Warfarin | 60 mg; 3 mg | 2; 1 | No | ||||
| 140 | No | Heparin calcium | 5,000 u | 2 | Yes | 7 | |||
| 141 | No | Enoxaparin; Warfarin | 60 mg; 3.25 mg | 2; 1 | No | ||||
| 142 | No | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3 mg | 2; 1 | No | ||||
| 143 | Yes | Enoxaparin; Warfarin | 40 mg; 2.25 mg | 2; 1 | Alteplase | 50 mg | Once | No | |
| 144 | Yes | Low molecular weight heparin calcium; Warfarin | 4,250 iu; 3 mg | 2; 1 | No | ||||
| 145 | No | Enoxaparin | 40 mg | 2 | No |
Acknowledgements
Funding: None.
Footnote
Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/amj.2017.02.11). The work is partially presented as a poster in the Asian Pacific Association for the Study of the Liver Single Topic Conference—6th HBV Conference, Beijing, China. Dr. Qi serves as an Editor-in-Chief of AME Medical Journal. The other authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The protocol of our study was approved by the Ethics Committee of General Hospital of Shenyang Military Area (approval number: k201602). Informed written consents were waived.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163-74. [Crossref] [PubMed]
- Goldhaber SZ. Pulmonary embolism. Lancet 2004;363:1295-305. [Crossref] [PubMed]
- Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98:756-64. [PubMed]
- Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006;21:23-9. [Crossref] [PubMed]
- Cronin-Fenton DP, Søndergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010;103:947-53. [Crossref] [PubMed]
- Jang MJ, Bang SM, Oh D. Incidence of pregnancy-associated venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemost 2011;9:2519-21. [Crossref] [PubMed]
- Lee CH, Lin LJ, Cheng CL, et al. Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population. J Thromb Haemost 2010;8:1515-23. [Crossref] [PubMed]
- Lee CH, Cheng CL, Lin LJ, et al. Epidemiology and predictors of short-term mortality in symptomatic venous thromboembolism. Circ J 2011;75:1998-2004. [Crossref] [PubMed]
- Zhang X, Qi X, De Stefano V, et al. Epidemiology, Risk Factors, and In-Hospital Mortality of Venous Thromboembolism in Liver Cirrhosis: A Single-Center Retrospective Observational Study. Med Sci Monit 2016;22:969-76. [Crossref] [PubMed]
- Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-15. [Crossref] [PubMed]
- Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007;167:935-43. [Crossref] [PubMed]
- Smeeth L, Cook C, Thomas S, et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006;367:1075-9. [Crossref] [PubMed]
- Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 2003;101:1243-8. [Crossref] [PubMed]
- Sweetland S, Green J, Liu B, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ 2009;339:b4583. [Crossref] [PubMed]
- Roach RE, Lijfering WM, Flinterman LE, et al. Increased risk of CVD after VT is determined by common etiologic factors. Blood 2013;121:4948-54. [Crossref] [PubMed]
- Barsoum MK, Heit JA, Ashrani AA, et al. Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thromb Res 2010;126:373-8. [Crossref] [PubMed]
- Bezemer ID, van der Meer FJ, Eikenboom JC, et al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009;169:610-5. [Crossref] [PubMed]
- Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92:199-205. [Crossref] [PubMed]
- Spencer FA, Gore JM, Lessard D, et al. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch Intern Med 2008;168:425-30. [Crossref] [PubMed]
- Smith SB, Geske JB, Maguire JM, et al. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 2010;137:1382-90. [Crossref] [PubMed]
- Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-9. [Crossref] [PubMed]
- Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med 2010;363:266-74. [Crossref] [PubMed]
- Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445-53. [Crossref] [PubMed]
- Verso M, Agnelli G, Ageno W, et al. Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. Thromb Res 2012;130:369-73. [Crossref] [PubMed]
- Qi X, Li H, Chen J, et al. Serum Liver Fibrosis Markers for Predicting the Presence of Gastroesophageal Varices in Liver Cirrhosis: A Retrospective Cross-Sectional Study. Gastroenterol Res Pract 2015;2015:274534.
- Qi X, Peng Y, Li H, et al. Diabetes is associated with an increased risk of in-hospital mortality in liver cirrhosis with acute upper gastrointestinal bleeding. Eur J Gastroenterol Hepatol 2015;27:476-7. [Crossref] [PubMed]
- Peng Y, Qi X, Dai J, et al. Child-Pugh versus MELD score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis. Int J Clin Exp Med 2015;8:751-7. [PubMed]
- Zhu C, Qi X, Li H, et al. Correlation of serum liver fibrosis markers with severity of liver dysfunction in liver cirrhosis: a retrospective cross-sectional study. Int J Clin Exp Med 2015;8:5989-98. [PubMed]
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. [Crossref] [PubMed]
- Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87. [Crossref] [PubMed]
- Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9. [Crossref] [PubMed]
- Schulman S, Kearon CSubcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4. [Crossref] [PubMed]
- Puurunen MK, Gona PN, Larson MG, et al. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res 2016;145:27-33. [Crossref] [PubMed]
- Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006;21:722-7. [Crossref] [PubMed]
- Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383:1749-61. [Crossref] [PubMed]
- Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S.
- Cerini F, Gonzalez JM, Torres F, et al. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology 2015;62:575-83. [Crossref] [PubMed]
- Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010;44:448-51. [PubMed]
- Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012;10:776-83. [Crossref] [PubMed]
- Qi X, De Stefano V, Li H, et al. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med 2015;26:23-9. [Crossref] [PubMed]
- Qi X, De Stefano V, Guo X. Anticoagulation with intravenous unfractionated heparin and major bleeding in cirrhosis. Hepatology 2016;64:2269-70. [Crossref] [PubMed]
- Qi X, De Stefano V, Guo X. Quality of anticoagulation and outcome of bleeding in cirrhosis. Hepatology 2016;64:320-1. [Crossref] [PubMed]
Cite this article as: Zhang X, Qi X, De Stefano V, Zhu Z, Qiao R, Guo X. Impact of liver cirrhosis on the outcomes of patients with venous thromboembolism: a case-control study. AME Med J 2017;2:26.
